Expression of programmed death 1 (PD-1) and its ligand (PD-L1) in thymic epithelial tumors: impact on treatment efficacy and alteration in expression after chemotherapy

Highlights • PD-L1 was positive in 67% of thymoma (TM) and 41% of thymic carcinoma (TC). • Changes in PD-L1 expression were evaluated in TM/TCs by the antibody (E1L3N). • Chemotherapy induced the expression of PD-L1 and PD-1 in TMs. • Immune check point therapies were warranted in TM/TCs.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Lung cancer (Amsterdam, Netherlands) Netherlands), 2016-09, Vol.99, p.4-10
Hauptverfasser:	Katsuya, Yuki, Horinouchi, Hidehito, Asao, Tetsuhiko, Kitahara, Shinsuke, Goto, Yasushi, Kanda, Shintaro, Fujiwara, Yutaka, Nokihara, Hiroshi, Yamamoto, Noboru, Watanabe, Shun-ichi, Tsuta, Koji, Ohe, Yuichiro
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antineoplastic Agents - therapeutic use Antineoplastic Combined Chemotherapy Protocols - therapeutic use B7-H1 Antigen - genetics B7-H1 Antigen - metabolism Biomarkers, Tumor Chemotherapy Combined Modality Therapy Female Gene Expression Hematology, Oncology and Palliative Medicine Humans Immunogenicity Immunohistochemistry Male Middle Aged Neoplasms, Glandular and Epithelial - drug therapy Neoplasms, Glandular and Epithelial - genetics Neoplasms, Glandular and Epithelial - metabolism Neoplasms, Glandular and Epithelial - mortality PD-1 PD-L1 Prognosis Programmed Cell Death 1 Receptor - genetics Programmed Cell Death 1 Receptor - metabolism Pulmonary/Respiratory Thymic carcinoma Thymoma Thymus Neoplasms - drug therapy Thymus Neoplasms - genetics Thymus Neoplasms - metabolism Thymus Neoplasms - mortality Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highlights • PD-L1 was positive in 67% of thymoma (TM) and 41% of thymic carcinoma (TC). • Changes in PD-L1 expression were evaluated in TM/TCs by the antibody (E1L3N). • Chemotherapy induced the expression of PD-L1 and PD-1 in TMs. • Immune check point therapies were warranted in TM/TCs.
ISSN:	0169-5002 1872-8332
DOI:	10.1016/j.lungcan.2016.05.007